In the beginning, anti-CAFs-DMS-AptT might not be able to bring CD8+ T lymphocytes into pancreatic tumor tissues, nevertheless, antiCAFs-DMS-AptT can still deliver AG17724 into CAFs and thus disrupt the immunosuppressive TME of pancreatic cancer, rendering it “reachable” and “reactive” by immune cells. This evidence concerns the gene CD8A and pancreatic neoplasm.